Shanghai Kaibao Pharmaceutical Co (SZSE:300039) Total Liabilities : ¥507 Mil (As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Shanghai Kaibao Pharmaceutical Co Total Liabilities?

Shanghai Kaibao Pharmaceutical Co's Total Liabilities for the quarter that ended in Mar. 2024 was ¥507 Mil.

Shanghai Kaibao Pharmaceutical Co's quarterly Total Liabilities declined from Sep. 2023 (¥580.67 Mil) to Dec. 2023 (¥546.82 Mil) and declined from Dec. 2023 (¥546.82 Mil) to Mar. 2024 (¥507.29 Mil).

Shanghai Kaibao Pharmaceutical Co's annual Total Liabilities increased from Dec. 2021 (¥310.91 Mil) to Dec. 2022 (¥498.24 Mil) and increased from Dec. 2022 (¥498.24 Mil) to Dec. 2023 (¥546.82 Mil).

Shanghai Kaibao Pharmaceutical Co Total Liabilities Historical Data

The historical data trend for Shanghai Kaibao Pharmaceutical Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Kaibao Pharmaceutical Co Total Liabilities Chart

Shanghai Kaibao Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

273.01

298.96

310.91

498.24

546.82

Shanghai Kaibao Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															642.78	639.07	580.67	546.82	507.29

Shanghai Kaibao Pharmaceutical Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Shanghai Kaibao Pharmaceutical Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	334.846	+	(0	+	211.971
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	547

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	4579.673	-	4032.856
	=	547

Shanghai Kaibao Pharmaceutical Co's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	357.392	+	(0	+	149.902
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	507

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	4286.989	-	3779.696
	=	507

Shanghai Kaibao Pharmaceutical Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Shanghai Kaibao Pharmaceutical Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Kaibao Pharmaceutical Co (SZSE:300039) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Kaibao Pharmaceutical Co Ltd (SZSE:300039) » Definitions » Total Liabilities

Traded in Other Exchanges

N/A

Address

88 Chengpu Road, Shanghai Industrial Comprehensive Development Zone, Shanghai, CHN, 201401

Website

http://www.xykb.com

Shanghai Kaibao Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in research, development, production, and sales of modern Chinese medicine. The company produces traditional Chinese medicines in the form of solid dosage, oral liquids, and small volume injections. Its main product is Tanreqing injection is mainly used for pneumonia, acute and chronic bronchitis and upper respiratory tract infection.

Executives

Liu Shao Yong	Supervisors
Ren Li Wang	Secretary Dong
Zhang Tao	Executives
Mu Jing Wei	Director
Li Xiu Hai	Directors, executives
Zhang Lian Xin	Supervisors
Han Jing	Independent director
Wang Guo Ming	Directors, executives
Wang Chong Bang	Executives
Liu Yi Shan	Director
Li Qing Wei	Independent director
Mu Lai An	Director
Zhu Ying Jun	Executives
Chang Qing Ling	Supervisors
Zhang Peng	Director

Shanghai Kaibao Pharmaceutical Co (SZSE:300039) Headlines

No Headlines